Status:
COMPLETED
Gradual Withdrawal of Remifentanil Infusion Reduced Postoperative Pain and Opioid Requirement During Breast Surgery
Lead Sponsor:
Samsung Medical Center
Conditions:
Pain, Postoperative
Eligibility:
FEMALE
20-80 years
Phase:
NA
Brief Summary
Although remifentanil provides profound analgesia during operation, postoperative occurrence of hyperalgesia and tolerance after remifentanil administration could be a challenge to the postoperative p...
Detailed Description
Patients were randomized into either SPI-guided analgesia or standard practice (Control). In both groups, anesthesia was maintained with total intravenous anaesthesia(TIVA) to keep bispectral index va...
Eligibility Criteria
Inclusion
- Patients who received the breast conserving surgery
Exclusion
- Patients with arrhythmia who have poor SPI measurement
- When the patient refused
- Patients with decreased renal function of Cr\> 2
- Surgery for more than 3 hours, surgery expected to bleed more than 500 ml
Key Trial Info
Start Date :
November 26 2018
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 3 2019
Estimated Enrollment :
60 Patients enrolled
Trial Details
Trial ID
NCT03756233
Start Date
November 26 2018
End Date
July 3 2019
Last Update
September 11 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Samsung Medical Center
Seoul, Gangnam-gu, South Korea, 06351